Literature DB >> 17056344

Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy.

Georgios K Efthimiadis1, Georgios Giannakoulas, Despina G Parharidou, Haralampos I Karvounis, Soterios T Mochlas, Ioannis H Styliadis, Stavros Gavrielides, Konstantinos D Gemitzis, Georgios D Giannoglou, Georgios E Parharidis, Georgios E Louridas.   

Abstract

Hypertrophic cardiomyopathy (HC) may transition to a phase characterized by systolic impairment resembling dilated cardiomyopathy. This study retrospectively assessed the incidence of left ventricular (LV) systolic impairment at initial clinical evaluation in 248 consecutive patients with HC (mean age 53 +/- 16 years). HC with systolic impairment was diagnosed if the LV ejection fraction was <50%, calculated by echocardiography. Twenty patients (8%) had HC with LV systolic impairment at initial evaluation. Patients with systolic impairment had a greater incidence of family histories of sudden cardiac death (SCD) than patients with preserved systolic function (25% vs 5.3%, p = 0.006) and more severe functional limitations (New York Heart Association class >or=III, p <0.001). All-cause mortality and cardiovascular mortality did not differ between the 2 groups. The incidence of SCD was 1.7% in patients with normal LV ejection fractions, and no SCD was observed in patients with systolic impairment. The latter group had more frequent major cardiac events (SCD, ventricular fibrillation, aborted cardiac arrest, and first implantable cardioverter-defibrillator discharge; p = 0.03). During follow-up, 2 patients progressed to HC with systolic impairment (annual incidence 0.85%). In conclusion, systolic impairment is not exceptional in patients with HC at initial evaluation and is associated with functional deterioration and major cardiac events.

Entities:  

Mesh:

Year:  2006        PMID: 17056344     DOI: 10.1016/j.amjcard.2006.05.063

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.

Authors:  Minako Takeda; Yasuo Amano; Masaki Tachi; Hitomi Tani; Kyoichi Mizuno; Shinichiro Kumita
Journal:  Jpn J Radiol       Date:  2013-08-31       Impact factor: 2.374

2.  Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.

Authors:  Georgios K Efthimiadis; Areti Hitoglou-Makedou; Georgios Giannakoulas; Anastasia Mitakidou; Theodoros Karamitsos; Haralambos Karvounis; Sotirios Mochlas; Ioannis Styliadis; Haris Stefanidis; Georgios Parcharidis; Georgios Louridas
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

3.  Hypertrophic cardiomyopathy and sudden cardiac death.

Authors:  Konstantinos I Stroumpoulis; Ioannis N Pantazopoulos; Theodoros T Xanthos
Journal:  World J Cardiol       Date:  2010-09-26

Review 4.  Evolving anatomic, functional, and molecular imaging in the early detection and prognosis of hypertrophic cardiomyopathy.

Authors:  Valentin Fuster; Sarina van der Zee; Marc A Miller
Journal:  J Cardiovasc Transl Res       Date:  2009-10-16       Impact factor: 4.132

5.  Long-Term Survival Following Cardiac Arrest Without Implantable Defibrillator Protection in a Hypertrophic Cardiomyopathy Patient.

Authors:  Mustafa Cetin; Ozgul Ucar; Alper Canbay; Zehra Guven Cetin; Hulya Cicekcioglu; Erdem Diker
Journal:  Cardiol Res       Date:  2011-05-20

6.  Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy.

Authors:  Jie Liu; Dong Wang; Jieyun Ruan; Guixin Wu; Lianjun Xu; Wen Jiang; Jizheng Wang; Xiaolu Sun; Lianming Kang; Lei Song
Journal:  BMC Med       Date:  2022-01-26       Impact factor: 8.775

7.  Subaortic and midventricular obstructive hypertrophic cardiomyopathy with extreme segmental hypertrophy.

Authors:  Georgios K Efthimiadis; Georgios Giannakoulas; Despina G Parcharidou; Antonios G Ziakas; Christodoulos E Papadopoulos; Takis Karoulas; Christodoulos Pliakos; Georgios Parcharidis
Journal:  Cardiovasc Ultrasound       Date:  2007-03-12       Impact factor: 2.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.